<DOC>
	<DOC>NCT00622713</DOC>
	<brief_summary>This study is designed to confirm the efficacy, the tolerability, the patient compliance and the caregiver satisfaction with rivastigmine target patch size 10 cm^2 in patients with probable Alzheimer's Disease (Mini-Mental State Examination 10-26) in the community setting</brief_summary>
	<brief_title>A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Males, and females of at least 50 years old with a primary caregiver Probable Alzheimer's disease MiniMental State Examination (MMSE) score of ≥ 10 and ≤ 26 Patients initiating therapy for the first time with a Cholinesterase (ChE) inhibitor (patients prescribed both rivastigmine and memantine are allowed) or patients who failed to benefit from previous ChE inhibitor treatment Residing with someone in the community throughout the study or, if living alone, in contact with the responsible caregiver everyday Patients not treated according to the product monograph for capsules Current diagnosis of an active skin lesion/disorder that would prevent accurate assessment of the adhesion and potential skin irritation of the patch (e.g., atopic dermatitis, wounded or scratched skin in the area of the patch application) History of allergy to topical products containing any of the constituents of the patches Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>cholinesterase inhibitor</keyword>
	<keyword>rivastigmine</keyword>
</DOC>